Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 5 | 2024 | 114 | 2.340 |
Why?
|
| Endometrial Neoplasms | 9 | 2023 | 72 | 1.550 |
Why?
|
| Laparoscopy | 6 | 2022 | 194 | 1.390 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2023 | 8 | 1.150 |
Why?
|
| Carcinosarcoma | 3 | 2022 | 8 | 1.010 |
Why?
|
| Uterine Neoplasms | 3 | 2022 | 32 | 1.000 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 402 | 0.910 |
Why?
|
| Bleomycin | 1 | 2024 | 13 | 0.870 |
Why?
|
| Etoposide | 1 | 2024 | 43 | 0.860 |
Why?
|
| Carboplatin | 1 | 2024 | 55 | 0.850 |
Why?
|
| Paclitaxel | 1 | 2024 | 73 | 0.850 |
Why?
|
| Cisplatin | 1 | 2024 | 88 | 0.840 |
Why?
|
| Sexual Harassment | 2 | 2024 | 5 | 0.810 |
Why?
|
| Gynecology | 2 | 2024 | 20 | 0.790 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 214 | 0.690 |
Why?
|
| Genital Neoplasms, Female | 4 | 2023 | 30 | 0.680 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 491 | 0.670 |
Why?
|
| Adenosarcoma | 1 | 2020 | 1 | 0.660 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2020 | 3 | 0.660 |
Why?
|
| Leiomyosarcoma | 1 | 2020 | 10 | 0.650 |
Why?
|
| Female | 30 | 2025 | 21531 | 0.610 |
Why?
|
| DNA Mismatch Repair | 4 | 2023 | 10 | 0.590 |
Why?
|
| Genes, BRCA1 | 1 | 2018 | 8 | 0.570 |
Why?
|
| Genes, BRCA2 | 1 | 2018 | 10 | 0.570 |
Why?
|
| Workplace | 1 | 2019 | 52 | 0.570 |
Why?
|
| Postoperative Complications | 3 | 2022 | 850 | 0.570 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2023 | 45 | 0.530 |
Why?
|
| Humans | 33 | 2025 | 34562 | 0.490 |
Why?
|
| Hysterectomy | 4 | 2022 | 55 | 0.410 |
Why?
|
| Mutation | 5 | 2024 | 532 | 0.390 |
Why?
|
| Opioid-Related Disorders | 2 | 2023 | 69 | 0.360 |
Why?
|
| Middle Aged | 9 | 2025 | 12726 | 0.290 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 98 | 0.280 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 103 | 0.280 |
Why?
|
| Microsatellite Instability | 3 | 2022 | 5 | 0.270 |
Why?
|
| Young Adult | 3 | 2024 | 2831 | 0.250 |
Why?
|
| Adult | 7 | 2025 | 10030 | 0.240 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2025 | 6 | 0.220 |
Why?
|
| Retrospective Studies | 9 | 2023 | 3825 | 0.220 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2024 | 2 | 0.220 |
Why?
|
| Aged | 6 | 2025 | 11022 | 0.220 |
Why?
|
| Vaginal Neoplasms | 1 | 2024 | 2 | 0.210 |
Why?
|
| Vulvar Neoplasms | 1 | 2024 | 8 | 0.210 |
Why?
|
| Obstetrics | 1 | 2024 | 28 | 0.210 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2023 | 2 | 0.200 |
Why?
|
| Disease-Free Survival | 2 | 2022 | 354 | 0.200 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2022 | 9 | 0.190 |
Why?
|
| Melanoma | 1 | 2024 | 170 | 0.190 |
Why?
|
| Hormones | 1 | 2022 | 26 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2022 | 19 | 0.190 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2022 | 6 | 0.180 |
Why?
|
| Neoplasms | 2 | 2020 | 793 | 0.180 |
Why?
|
| Receptor, erbB-2 | 1 | 2022 | 70 | 0.180 |
Why?
|
| Genomics | 1 | 2022 | 94 | 0.180 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 225 | 0.180 |
Why?
|
| Sterilization, Tubal | 1 | 2021 | 6 | 0.170 |
Why?
|
| Endometrial Ablation Techniques | 1 | 2020 | 5 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2020 | 46 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 89 | 0.160 |
Why?
|
| Infection Control | 1 | 2020 | 29 | 0.160 |
Why?
|
| Peritoneal Neoplasms | 1 | 2023 | 265 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2021 | 126 | 0.160 |
Why?
|
| Cesarean Section | 1 | 2021 | 122 | 0.160 |
Why?
|
| Uterus | 1 | 2020 | 106 | 0.160 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2020 | 50 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2020 | 94 | 0.150 |
Why?
|
| Genetic Techniques | 1 | 2019 | 8 | 0.150 |
Why?
|
| Biopsy | 1 | 2020 | 273 | 0.150 |
Why?
|
| Societies, Medical | 1 | 2019 | 168 | 0.140 |
Why?
|
| Internet | 1 | 2019 | 207 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 431 | 0.130 |
Why?
|
| Physicians | 1 | 2019 | 169 | 0.130 |
Why?
|
| Prognosis | 1 | 2020 | 1606 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 486 | 0.120 |
Why?
|
| United States | 2 | 2024 | 4278 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3623 | 0.110 |
Why?
|
| Male | 4 | 2025 | 20739 | 0.090 |
Why?
|
| Patient Discharge | 2 | 2022 | 214 | 0.080 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 265 | 0.080 |
Why?
|
| Length of Stay | 2 | 2021 | 335 | 0.080 |
Why?
|
| Pain, Postoperative | 2 | 2022 | 205 | 0.070 |
Why?
|
| Lanosterol | 1 | 2025 | 1 | 0.060 |
Why?
|
| Sitosterols | 1 | 2025 | 2 | 0.060 |
Why?
|
| Canada | 1 | 2024 | 69 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2025 | 186 | 0.050 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2023 | 5 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2025 | 597 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2023 | 10 | 0.050 |
Why?
|
| Language | 1 | 2023 | 45 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 92 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 48 | 0.050 |
Why?
|
| Gene Amplification | 1 | 2022 | 10 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2022 | 48 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 232 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1034 | 0.040 |
Why?
|
| Narcotics | 1 | 2021 | 32 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 35 | 0.040 |
Why?
|
| Markov Chains | 1 | 2021 | 32 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2020 | 74 | 0.040 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 11 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2020 | 98 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 24 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 197 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 82 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2020 | 120 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2021 | 98 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 271 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 590 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 31 | 0.040 |
Why?
|
| Decision Making | 1 | 2020 | 203 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2023 | 649 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1032 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 565 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 3805 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 4157 | 0.020 |
Why?
|